This inventor holds 2 USPTO granted patents. Top assignees: Zymogenetics, Inc., Other. Active years: 2001-2003.
Company Filing History:
1 out of 723 
1 out of 834,350 Years Active: 2001-2003
Title: The Innovations of James M LaGasse
Introduction
James M LaGasse is a notable inventor based in Seattle, WA (US). He has made significant contributions to the field of biomedical research, particularly in the area of diabetes. With a total of 2 patents, LaGasse's work has had a meaningful impact on the understanding and treatment of insulin-dependent diabetes mellitus (IDDM).
Latest Patents
LaGasse's latest patents include the development of Islet Cell Antigen 1851. This mammalian islet cell antigen polypeptide plays a crucial role in the development of IDDM. The polypeptide was found to contain regions of homology to the protein tyrosine phosphatase family. His patents present methods for diagnosis and treatment, including the use of immunoprecipitation assays and the induction of immune tolerance through recombinant mammalian polypeptides and antibodies specific to Islet Cell Antigen 1851.
Career Highlights
Throughout his career, LaGasse has worked with various companies, including Zymogenetics, Inc. His expertise in the field has allowed him to contribute to important research and development projects that advance medical science.
Collaborations
LaGasse has collaborated with notable coworkers such as Wayne R Kindsvogel and Laura J Jelinek. These partnerships have further enriched his research and innovation efforts.
Conclusion
James M LaGasse's contributions to the field of diabetes research through his patents and collaborations highlight his role as a significant inventor. His work continues to influence the medical community and improve the lives of those affected by diabetes.